Clinical Trial Update: Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

A prospective, multicenter, single-arm Phase 2 trial is evaluating sacituzumab tirumotecan plus bevacizumab for platinum-resistant recurrent ovarian cancer and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Recurrent Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Platinum-resistant Recurrent Ovarian Cancer (PROC) | Phase 2 | Status: NOT_YET_RECRUITING